Anti Colton-A Foeto-Neonatal Haemolytic Disesase: Diagnosis; Clinical Outcome and Family Study
International Blood Research & Reviews, Volume 14, Issue 1,
Page 29-37
DOI:
10.9734/ibrr/2023/v14i1299
Abstract
The authors report a case of neonatal haemolytic disease (HDN) attributable to maternal allo immunization to a high frequency antigen present on paternal red blood cells which have been identified as Colton-a (Coa).
The case seemed worthy of reporting not only for the relative rarity of HDN from anti Coa but for the rigorous approach followed in the immunohaematological follow-up of pregnancy and for the diagnostic effort expended in identifying the specificity of the antibody. A family study of ascendants, collaterals and descendants was also carried out using genotyping techniques.
- Anti-Coa
- family study
- genotyping
- HDFN
How to Cite
References
Milkins C, Berryman J, Cantwell C, et al. Guidelines for pre-transfusion compatibility procedures in blood transfusion laboratories. British Committee for Standards in Hematology. Transfus Med. 2013;23(1):3–35.
DOI:10.1111/j.1365-3148.2012.01199.x
Basu S, Kaur R, Kaur G. Hemolytic disease of the fetus and newborn: current trends and perspectives. Asian J Transfus Sci. 2011;5 (1):3–7.
DOI:10.4103/0973-6247.75963
Jackson ME, Baker JM. Hemolytic disease of the fetus and newborn: historical and current state. Clin Lab Med. 2021;41:133-151.
DOI: 10.1016/j.cll.2020.10.009.
Dziegiel M, Krog G, Hansen AT, Olsen M, Lausen B, Nørgaard L, et al. Laboratory monitoring of mother, fetus, and newborn in hemolytic disease of fetus and newborn. Transfus Med Hemother. 2021;48:306-315.
DOI: 10.1159/000518782
Matteocci A, De Rosa A, Buffone E, Pierelli L. Retrospective analysis of HDFN due to ABO incompatibility in a single institution over 6 years. Transfus Med. 2019;29:197-201.
DOI: 10.1111/tme.12512.
Castleman J, Moise K Jr, Kilby M. Medical therapy to attenuate fetal anaemia in severe maternal red cell alloimmunisation. Br J Haematol. 2021;192:425-432.
DOI: 10.1111/bjh.17041.
De Winter D, Hulzebos C, Van't Oever R, De Haas M, Verweij E, Lopriore E. History and current standard of postnatal management in hemolytic disease of the fetus and newborn. Eur J Pediatr; 2022.
DOI: 10.1007/s00431-022-04724-0.
Chavez GF, Mulinare J, Edmonds LD. Epidemiology of Rh hemolytic disease of the newborn in the United States. J Am Med Assoc. 1991;265(24):3270–3274.
DOI:10.1001/jama.1991.03460240066029
Liumbruno GM, D’alessandro A, Rea F, et al. The role of antenatal immunoprophylaxis in the prevention of maternal foetal anti Rh (D) alloimmunisation. Blood Transfus. 2010;8(1):8–16. DOI:10.2450/ 2009.0108-09.
Singh B, Chaudhary R, Elhence P, Bharati J, Srivastava A. A case report on non-D HDFN: Highlighting the role of antibody screening in RhD positive antenatal women. Asian J Transfus Sci. 2022;16:121-123.
DOI: 10.4103/ajts.ajts_108_21.
Dajak S, Stefanović V, Capkun V. Severe hemolytic disease of fetus and newborn caused by red blood cell antibodies undetected at first-trimester screening. Transfusion. 2011;51(7):1380–1388.
DOI:10.1111/j.1537- 2995.2010.03006.x
Smith HM, Shirey RS, Thoman SK, Jackson JB. Prevalence of clinically significant red blood cell alloantibodies in pregnant women at a large tertiary-care facility. Immunohematology. 2013;29 (4):127–130.
Solves P, Gomez-Segui I, Guinot M, et al. Prevalence of red cell antibodies in pregnant women and hemolytic disease of newborn in a tertiary care hospital. ARC J Gynaecol Obstet. 2017;2(2):18–22.
Erikstein BS, Hagen KG, Hervig T. RBC alloantibody prevalence and specificity in a Western Norwegian tertiary hospital. Transfus Med; 2018.
DOI:10.1111/tme.12511
Heistö H, van der Hart M, Madsen G, et al. Three examples of a new red cell antibody, anti-Coa. Vox Sang. 1967;12:18–24.
Reid ME, Lomas-Francis C. The blood group antigen factsbook. 2nd ed. San Diego, CA: Academic Press; 2004.
Wray E, Simpson S. A further example of anti-Coa and two informative families with Co (a–) members. Vox Sang. 1968;14:130–2.
Smith BL, Preston GM, Spring FA, Anstee DJ, Agre P. Human red cell aquaporin CHIP. I. Molecular characterization of ABH and Colton blood group antigens. J Clin Invest. 1994;94:1043–9.
Giles CM, Darnborough J, Aspinall P, Fletton MW. Identification of the first example of anti-Cob. Br J Haematol. 1970;19:267–9.
Lewis M, Kaita H, Anderson C, Chown B. Independence of Colton blood group. Transfusion. 1971;11:223–4.
Zelinski T, Kaita H, Gilson T, Coghlan G, Philipps S, Lewis M. Linkage between the Colton blood group locus and ASSP11 on chromosome 7. Genomics. 1990;6:623–5.
Kurtz SR, Kuszaj T, Ouellet R, Valeri CR. Survival of homozygous Coa (Colton) red cells in a patient with anti-Coa. Vox Sang. 1982;43:28–30.
Covin RB, Evans KS, Olshock R, Thompson HW. Acute hemolytic transfusion reaction caused by anti-Coa. Immunohematology. 2001;17:45–9.
Simpson WKH. Anti-Coa and severe haemolytic disease of the newborn. S Afr Med J. 1973;47:1302–4.
Michalewska B, Wielgos M, Zupanska B, Bartkowiak R. Anti-Coa implicated in severe haemolytic disease of the foetus and newborn. Transfus Med. 2008;18:71–3.
Kimmich N, Brand B, Hustinx H, Komarek A, Zimmermann R. Management of anti-Colton(a) alloimmunisation in pregnancy: a case report. Transfus Med. 2016;26:150-2.
DOI: 10.1111/tme.12287.
Van't Oever R, Zwiers C, de Winter D, de Haas M, Oepkes D, Lopriore E, et al. Verweij. Identification and management of fetal anemia due to hemolytic disease. Expert Rev Hematol. 2022;15:987-998.
DOI: 10.1080/17474086.2022.2138853.
Kjeldsen-Kragh J, Hellberg Å(1). Noninvasive prenatal testing in immunohematology-clinical, technical and ethical considerations. J Clin Med. 2022;11(10):2877.
DOI: 10.3390/jcm11102877.
-
Abstract View: 51 times
PDF Download: 35 times
